FIP antiviral success brings a new stewardship challenge: full analysis

A new warning from infectious disease specialist Scott Weese is putting antiviral stewardship squarely into the FIP conversation: now that GS-441524 has changed feline infectious peritonitis from an almost invariably fatal disease into one that is often treatable, the profession needs to protect that gain. In his March 4, 2025 Worms & Germs analysis, Weese said the main resistance threat is not standard treatment of cats with FIP itself, but wider use of GS-441524 in cats carrying enteric feline coronavirus, where resistant virus could emerge in the intestine and then circulate between cats. (wormsandgermsblog.com)

That warning comes against a backdrop of rapid change in FIP care. The updated ABCD guidance says prompt antiviral treatment, typically with the nucleoside analogue GS-441524, has revolutionized outcomes, and it frames FIP as a treatable, frequently curable disease rather than an automatic euthanasia discussion. Earlier treatment guidance highlighted another shift in practice: more emphasis on oral GS-441524 alone, with twice-daily dosing in some protocols, and less routine reliance on induction remdesivir except in cats that are critically ill or may not absorb oral drugs well. (abcdcatsvets.org)

The core of Weese’s argument is epidemiologic. Feline coronavirus is common and readily transmitted by the fecal-oral route, but the FIP-causing form is generally considered only rarely transmissible. That means resistance emerging during treatment of an individual FIP case could be devastating for that cat, yet is unlikely to become a broad population problem if the resistant virus dies out with the host. By contrast, using GS-441524 against enteric feline coronavirus could select for resistance in a virus that is built to spread, creating the scenario clinicians most want to avoid: future FIP cases seeded by already resistant virus. (wormsandgermsblog.com)

Current guideline language broadly supports a cautious hierarchy of use. ABCD’s updated recommendations continue to center GS-441524, while noting that molnupiravir has shown good results, including reported rescue use after GS-441524 relapse, and that comparative studies have not shown significant differences in treatment outcome. At the same time, the guideline says some experts prefer GS-441524 over molnupiravir when possible, especially in non-effusive disease, and flags concerns about host mutagenesis from human literature. It also notes that molnupiravir was designated in the European Union in 2023 as an antimicrobial reserved for human use only, a policy point that could shape access and prescribing decisions. (abcdcatsvets.org)

Industry and expert reaction is converging on the same practical message: use these drugs thoughtfully. Weese’s formulation is blunt, arguing that treating enteric feline coronavirus offers little clinical benefit and little realistic eradication benefit while risking resistance against a “game-changing” drug. Meanwhile, treatment guidance he highlighted in 2024 pointed to more refined dosing strategies intended to reduce failures that may stem from variable absorption and metabolism, underscoring that stewardship is not simply about using less, but about using the right drug, at the right dose, in the right cat. (wormsandgermsblog.com)

Why it matters: For veterinary teams, this is a reminder that the FIP era now demands stewardship disciplines more familiar from antibiotic medicine. Diagnostic rigor matters, because unnecessary exposure still creates selective pressure if a cat happens to be carrying intestinal feline coronavirus. Dosing and monitoring matter, because underdosing or poorly optimized treatment may increase the chance of non-response or relapse. Client communication matters too: pet parents may hear that FIP is now curable, but the profession’s job is to preserve that reality by discouraging casual, off-label, or poorly justified antiviral use outside evidence-based protocols. (wormsandgermsblog.com)

There’s also a systems issue here. As legal access improves in some markets and more formulations become available, pressure may grow to use antivirals earlier, more broadly, or for conditions adjacent to FIP. That may be understandable, especially in multi-cat households and catteries where feline coronavirus is endemic, but Weese’s argument is that this is exactly where restraint matters most. The profession has a rare opportunity to build stewardship norms before resistance becomes entrenched. (wormsandgermsblog.com)

What to watch: The next phase will likely center on formal resistance surveillance, clearer rescue-therapy sequencing, and more standardized guidance on when to reserve agents such as molnupiravir or EIDD-1931 for relapse, treatment failure, or cases where GS-441524 is not suitable. (abcdcatsvets.org)